No Data
Allogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Highlights Presentation Of ALLO-329 Preclinical Data At American College of Rheumatology Convergence 2024
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Cuts Target Price to $9
Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $9
Allogene Therapeutics Analyst Ratings
Stifel Maintains Allogene Therapeutics(ALLO.US) With Hold Rating, Cuts Target Price to $4.5
No Data
No Data